Molecular and anatomic imaging continues to be an ever increasing and essential component of clinical drug trials. Early stage trials examine target accessibility and drug pharmacokinetics, while later phase studies employ imaging as an early indicator of response or as an efficacy endpoint. New molecular probes from early phase studies become the future diagnostic agents that guide patient stratification for therapy and monitor patient response.
BioMolecular Imaging can also serve in an advisory role for venture investments in imaging companies and for merger and acquisition activities. We can provide investment advice and strategic support for start-ups or for mature companies, including those focused on development of new diagnostics, imaging hardware, or image analytics.
Early clinical imaging examines factors such as organ penetration; drug target binding; biokinetics; and binding to sites for side effects and toxicity. These results stage the trial for subsequent extension or may result in stopping the trial, both of which have significant monetary implications.
Late clinical imaging trials are designed to examine biochemical and pharmacological correlates of clinical efficacy. Surrogate imaging biomarkers are also examined in late clinical trials. These aspects help make the case for drug approval and create a framework for patient treatment stratification and dosing.